An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/16/2019
Start Date:May 2009
End Date:December 2015

Use our guide to learn which trials are right for you!

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

The purpose of this study was to determine whether monthly deep subcutaneous (s.c.)
injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling
diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue
medication to control symptoms in subjects with carcinoid syndrome.

This study consisted of a Screening period, conducted up to 4 months before randomisation,
followed by three phases: a 16-week, double blind (DB), randomised, placebo-controlled phase;
a 32-week initial open label (IOL) phase; and a long term open label extension (LTOLE) phase.

The DB phase evaluated lanreotide Autogel versus placebo in subjects with a history of
carcinoid syndrome (flushing and/or diarrhoea). This was followed by a 32-week IOL phase in
which all subjects received lanreotide Autogel 120 mg every 4 weeks. Subjects in countries
where lanreotide Autogel had not been approved for the treatment of carcinoid syndrome, who
were well-controlled at the end of the 32-week IOL phase and chose to continue to receive
lanreotide Autogel, were given the option of participating in a LTOLE phase. The LTOLE phase
of the study was planned to end at least 2 years after the last subject had completed his/her
participation in the 32-week IOL phase or when marketing approval for the treatment of
symptoms of carcinoid syndrome had been obtained in the respective countries (whichever
occurred first) or at any time the study was terminated by the Sponsor. The actual overall
duration of the study was 6.5 years. During the LTOLE phase all subjects continued to be
treated with lanreotide Autogel 120 mg every 4 weeks.

The study planned to enrol approximately 100 adult subjects worldwide. Screening continued
until 115 subjects were enrolled in the study.

Subjects were eligible for participation in the study if they met the following criteria:

1. At least 18 years of age at the time of first dosing.

2. Subjects must have given signed informed consent before any study related activities
were conducted.

3. Subjects in the United States of America (USA) must have given written authorisation
for the release of protected health information in compliance with the Health
Insurance Portability and Accountability Act (HIPAA) regulations; subjects in other
countries must have provided appropriate authorisation as needed by regulatory
authorities in each country.

4. Subjects must have been willing to receive s.c. octreotide injections as rescue
medication, as needed to control their symptoms, if any.

5. If female, the subject must not have been pregnant (confirmed by negative pregnancy
test) and must have had the following documented via verbally given history:

- At least 1 year postmenopausal (natural cessation of menses), or

- Surgically sterile (if by tubal ligation, surgery must have been performed more
than 3 months prior to entry into the study), or

- If the subject was of childbearing potential and sexually active, she must have
been using an acceptable form of contraception (oral, injected, transdermal or
implanted contraceptives, diaphragm or barrier method with spermicidal and/or
intrauterine device); local methods such as condoms or sponges/vaginal tablets
were not acceptable forms of contraception.

6. Subjects with a histopathologically confirmed diagnosis of carcinoid tumour or, a
carcinoid tumour of unknown location with liver metastases (documented biopsy), and a
history of carcinoid syndrome (flushing and/or diarrhoea) who were either naïve to
treatment with a somatostatin analogue (SSTa) or responsive (according to the opinion
of the principal investigator) to conventional doses of Sandostatin LAR® Depot (LAR;
≤30 mg every 4 weeks) or to daily doses of ≤600 μg of s.c. octreotide.

7. Confirmation of positive somatostatin receptor (SSTR) status by somatostatin receptor
scintigraphy (SRS; up to 6 months prior to study entry at the Screening Visit).

8. Absence of tumour progression documented by two sequential computed tomography (CT)
scans or two sequential magnetic resonance imaging (MRI) scans (≥3 months apart); the
last CT or MRI scan must have been performed within 6 months of study entry (Screening
Visit).

9. Subjects previously treated with LAR, must have received their last dose of LAR at
least 4 weeks prior to first dose of study treatment (no later than at the Screening
Visit).

10. Be able to communicate and cooperate with the principal investigator and the staff and
willing to comply with the study instructions.

Subjects were excluded from entering the study for the following reasons:

1. History of known allergy or hypersensitivity to investigational drug or any components
of its formulation, or octreotide.

2. History of carcinoid syndrome refractory to treatment with conventional doses of SSTa.

3. Treatment with any other investigational drug within 30 days prior to study entry
(Screening Visit) and/or at any time during the subject's participation in the study.

4. Treatment with interferon, chemotherapy and/or radiotherapy (a radiolabelled SSTa)
and/or tumour debulking <3 months prior to study entry (Screening Visit).

5. History of hepatic arterial embolisation, hepatic arterial chemoembolisation and/or
selective internal radiation therapy (selective internal radiation [SIR] therapy
[SIRT]; e.g. SIR Spheres) <6 months prior to study entry (Screening Visit).

6. Short bowel syndrome.

7. Uncontrolled diabetes and/or hypertension.

8. Severe renal impairment (glomerular filtration rate <30 mL/min/1.73 m2) and/or severe
liver impairment as evidenced by serum total bilirubin >1.5 mg/dL associated with bile
duct blockage or with alkaline phosphatase (ALP), aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) >5.0 upper limit of normal (ULN).

9. Diagnosis of cardiac disease New York Heart Association (NYHA) functional
classification >Class I. (Subject has limitation of physical activity. Ordinary
physical activity causes undue fatigue, palpitation, or dyspnoea).

10. Life expectancy less than 1 year.

11. Any malignancies except carcinoid tumour, basocellular carcinoma of the skin, in situ
carcinoma of the cervix and ≥5 years disease free after curative cancer treatment.

12. Any serious medical condition that could jeopardise the safety of the subject and/or
the efficacy assessments of the study.

13. Subject is being treated with a proton pump inhibitor (PPI) and has been at a stable
dose (no change in dose or frequency of administration) for less than 4 weeks at study
entry (Screening Visit).
We found this trial at
17
sites
?
mi
from
Kenner, LA
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Norfolk, Virginia 23507
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Albuquerque, New Mexico 97239
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Belo Horizonte,
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90073
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
West Hollywood, California 90048
?
mi
from
West Hollywood, CA
Click here to add this to my saved trials